» Articles » PMID: 29303974

Immune-Mediated Mechanisms of Action of Probiotics and Synbiotics in Treating Pediatric Intestinal Diseases

Overview
Journal Nutrients
Date 2018 Jan 6
PMID 29303974
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The pediatric population is continually at risk of developing infectious and inflammatory diseases. The treatment for infections, particularly gastrointestinal conditions, focuses on oral or intravenous rehydration, nutritional support and, in certain case, antibiotics. Over the past decade, the probiotics and synbiotics administration for the prevention and treatment of different acute and chronic infectious diseases has dramatically increased. Probiotic microorganisms are primarily used as treatments because they can stimulate changes in the intestinal microbial ecosystem and improve the immunological status of the host. The beneficial impact of probiotics is mediated by different mechanisms. These mechanisms include the probiotics' capacity to increase the intestinal barrier function, to prevent bacterial transferation and to modulate inflammation through immune receptor cascade signaling, as well as their ability to regulate the expression of selected host intestinal genes. Nevertheless, with respect to pediatric intestinal diseases, information pertaining to these key mechanisms of action is scarce, particularly for immune-mediated mechanisms of action. In the present work, we review the biochemical and molecular mechanisms of action of probiotics and synbiotics that affect the immune system.

Citing Articles

The Role of the Microbiome and of Radiotherapy-Derived Metabolites in Breast Cancer.

Herrera-Quintana L, Vazquez-Lorente H, Silva R, Olivares-Arancibia J, Reyes-Amigo T, Pires B Cancers (Basel). 2024; 16(21).

PMID: 39518108 PMC: 11545256. DOI: 10.3390/cancers16213671.


Gut-brain axis and neurodegeneration: mechanisms and therapeutic potentials.

Park K, Gao Y Front Neurosci. 2024; 18:1481390.

PMID: 39513042 PMC: 11541110. DOI: 10.3389/fnins.2024.1481390.


Lactobacillus rhamnosus modulates murine neonatal gut microbiota and inflammation caused by pathogenic Escherichia coli.

Xuan H, Umar S, Zhong C, Yu W, Ahmed I, Wheatley J BMC Microbiol. 2024; 24(1):452.

PMID: 39506682 PMC: 11539828. DOI: 10.1186/s12866-024-03598-6.


Relationship between Infant Feeding and the Microbiome: Implications for Allergies and Food Intolerances.

Herrera-Quintana L, Vazquez-Lorente H, Hinojosa-Nogueira D, Plaza-Diaz J Children (Basel). 2024; 11(8).

PMID: 39201963 PMC: 11353207. DOI: 10.3390/children11081030.


The Role of the Microbiota in the Pathogenesis and Treatment of Atopic Dermatitis-A Literature Review.

Wrzesniewska M, Woloszczak J, Swirkosz G, Szyller H, Gomulka K Int J Mol Sci. 2024; 25(12).

PMID: 38928245 PMC: 11203945. DOI: 10.3390/ijms25126539.


References
1.
Hudson L, Anderson S, Corbett A, Lamb T . Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev. 2016; 30(1):191-231. PMC: 5217792. DOI: 10.1128/CMR.00049-16. View

2.
Gil-Campos M, Lopez M, Rodriguez-Benitez M, Romero J, Roncero I, Linares M . Lactobacillus fermentum CECT 5716 is safe and well tolerated in infants of 1-6 months of age: a randomized controlled trial. Pharmacol Res. 2011; 65(2):231-8. DOI: 10.1016/j.phrs.2011.11.016. View

3.
Esposito S, Umbrello G, Castellazzi L, Principi N . Treatment of Clostridium difficile infection in pediatric patients. Expert Rev Gastroenterol Hepatol. 2015; 9(6):747-55. DOI: 10.1586/17474124.2015.1039988. View

4.
Maldonado J, Canabate F, Sempere L, Vela F, Sanchez A, Narbona E . Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J Pediatr Gastroenterol Nutr. 2011; 54(1):55-61. DOI: 10.1097/MPG.0b013e3182333f18. View

5.
Liu S, Hu P, Du X, Zhou T, Pei X . Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. Indian Pediatr. 2013; 50(4):377-81. DOI: 10.1007/s13312-013-0123-z. View